OBJECTIVE: To develop a generalized cost-effectiveness analysis (GCEA) of the HPV vaccine, hybrid capture screening (HC) and Papanicolaou screening (Pap) in the Mexican context. MATERIALS AND METHODS: From April to August 2007, in Mexico, a GCEA of the interventions was developed for 10 possible scenarios using a Markov model from the public sector perspective as payer. RESULTS: Scenarios considering 80% coverage show an ACER per DALY averted of $16678 pesos for Pap of women between ages 25 and 64, $17277 pesos for HC of women between ages 30 and 64, and $84008 pesos for vaccination of 12-year-old girls. Annual financing of $621, $741 and $2255 million pesos, respectively, is needed for these scenarios. CONCLUSIONS: A selective, combined introduction of Pap-HC screening that considers the comparative advantages of application in different populations and geographical areas is suggested. Additionally, it is suggested to introduce the vaccine once a threshold price of $181 pesos per dose -when the vaccine becomes equal in terms of cost-effectiveness to HC- has been achieved.
OBJECTIVE: To develop a generalized cost-effectiveness analysis (GCEA) of the HPV vaccine, hybrid capture screening (HC) and Papanicolaou screening (Pap) in the Mexican context. MATERIALS AND METHODS: From April to August 2007, in Mexico, a GCEA of the interventions was developed for 10 possible scenarios using a Markov model from the public sector perspective as payer. RESULTS: Scenarios considering 80% coverage show an ACER per DALY averted of $16678 pesos for Pap of women between ages 25 and 64, $17277 pesos for HC of women between ages 30 and 64, and $84008 pesos for vaccination of 12-year-old girls. Annual financing of $621, $741 and $2255 million pesos, respectively, is needed for these scenarios. CONCLUSIONS: A selective, combined introduction of Pap-HC screening that considers the comparative advantages of application in different populations and geographical areas is suggested. Additionally, it is suggested to introduce the vaccine once a threshold price of $181 pesos per dose -when the vaccine becomes equal in terms of cost-effectiveness to HC- has been achieved.
Authors: Yvonne N Flores; David M Bishai; Attila Lorincz; Keerti V Shah; Eduardo Lazcano-Ponce; Mauricio Hernández; Víctor Granados-García; Ruth Pérez; Jorge Salmerón Journal: Cancer Causes Control Date: 2010-12-18 Impact factor: 2.506
Authors: Obinna I Ekwunife; James F O'Mahony; Andreas Gerber Grote; Christoph Mosch; Tatjana Paeck; Stefan K Lhachimi Journal: Pharmacoeconomics Date: 2017-01 Impact factor: 4.981
Authors: Brian C Castrucci; Alonso Echegollen Guzmán; Mona Saraiya; Brian R Smith; Kayan L Lewis; Steven S Coughlin; Ginger L Gossman; Jill A McDonald; Hillary Foulkes; Gita Mirchandani; Luz Correa-Nieto Canedo; Imelda M Garcia; Juan Acuña Journal: Prev Chronic Dis Date: 2008-09-15 Impact factor: 2.830